Chemed Q1 2024: Adjusted EPS $5.20 beats; VITAS EBITDA surges 67%, Roto-Rooter down 16%

CHEMED CORP

2024-Q1 EPS reported $4.24 revenue$589,233,000

Revenue +5.2% to $589.2M; GAAP EPS $4.24 (+18.4%); Adjusted EPS $5.20 (+21.5%)
VITAS net patient revenue +14% to $354M, ADC up 10.3% to 19,665; adjusted EBITDA +67.2% to $60.7M
Roto-Rooter revenue -5.8% to $235.2M, adjusted EBITDA -15.6% to $60.7M; margin down 299bps
Acquired Covenant Health hospice assets for $85M on Apr 17; no debt, $313.4M cash; bought back 50k shares for $32.3M
Full-year 2024 adjusted EPS guidance reaffirmed at $23.30-$23.70; next update with Q2 results

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CHEMED CORP reported first quarter ended March 31, 2024 results: revenue $589.2 million, EPS $4.24.

Period: first quarter ended March 31, 2024
Revenue: $589.2 million
EPS: $4.24
Result: reported results

Exact text from the filing

· Revenue increased 5.2% to $589.2 million · GAAP Diluted Earnings-per-Share (EPS) of $4.24, an increase of 18.4% · Adjusted Diluted EPS of $5.20, an increase of 21.5%

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

CHEMED CORP filing history →

Source: SEC EDGAR

accession 0001562762-24-000096

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.